CoChat
Sign Up
Cited by 42Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)

Open access
Fereshtehnejad, Seyed-Mohammad, Religa, Dorota, Westman, Lökk, Johan, Eriksdotter, Maria, Aarsland, Dag·2013·Neuropsychiatric Disease and Treatment
DOI 10.2147/ndt.s45840PMC PMC3700781
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Whether dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) should be considered as one entity or two distinct conditions is a matter of controversy. The aim of this study was to compare the characteristics of DLB and PDD patients using data from the Swedish Dementia Quality Registry (SveDem). METHODS: SveDem is a national Web-based quality registry initiated to improve the quality of diagnostic workup, treatment, and care of patients with dementia across Sweden. Patients with newly diagnosed dementia of various types were registered in SveDem during the years 2007-2011. The current cross-sectional report is based on DLB (n = 487) and PDD (n = 297) patients. Demographic characteristics, diagnostic workup, Mini-Mental State Examination (MMSE) score, and medications were compared between DLB and PDD groups. RESULTS: No gender differences were observed between the two study groups (P = 0.706). PDD patients were significantly younger than DLB patients at the time of diagnosis (74.8 versus 76.8 years, respectively; P < 0.001). A significantly higher prevalence of patients with MMSE score ≤24 were found in the PDD group (75.2% versus 67.6%; P = 0.030). The mean number of performed diagnostic modalities was significantly higher in the DLB group (4.9 ± 1.7) than in the PDD group (4.1 ± 1.6; P < 0.001). DLB patients were more likely than PDD patients to be treated with cholinesterase inhibitors (odds ratio = 2.5, 95% confidence interval = 1.8-3.5), whereas the use of memantine, antidepressants, and antipsychotics did not differ between the groups. CONCLUSION: This study demonstrates several differences in the dementia work-up between DLB and PDD. The onset of dementia was significantly earlier in PDD, while treatment with cholinesterase inhibitors was more common in DLB patients. Severe cognitive impairment (MMSE score ≤24) was more frequent in the PDD group, whereas more diagnostic tests were used to confirm a DLB diagnosis. Some similarities also were found, such as gender distribution and use of memantine, antidepressants, and antipsychotics drugs. Further follow-up cost-effectiveness studies are needed to provide more evidence for workup and treatment guidelines of DLB and PDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s45840

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DLB and PDD share pathological and clinical characteristics, are considered part of a continuum within the spectrum of LBD, and were therefore merged for this study as LBDs.

    “DLB and PDD share pathological and clinical characteristics, are considered part of a continuum within the spectrum of LBD [33, 34], and were therefore merged for this study as LBDs.”

    From Antidepressant use and cognitive decline in patients with dementia: a national cohort study (2025) · cites this paper as [33]

    The Introduction says DLB and PDD overlap clinically, and the Discussion notes that some studies found similar histopathological features. But the Introduction calls it controversial whether they are one entity or two distinct conditions; it does not establish that they form a continuum. The decision to merge them is the citing study’s own method, not a claim attributed to this source. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. [1]Perez F Helmer C Dartigues JF Auriacombe S Tison F A 15-year population-based cohort study of the incidence of Parkinson’s disease and dementia with Lewy bodies in an elderly French cohort J Neurol Neurosurg Psychiatry 2010 81 7 742 746 19965839
  2. [2]Aarsland D Andersen K Larsen JP Lolk A Nielsen H Kragh-Sørensen P Risk of dementia in Parkinson’s disease: a community-based, prospective study Neurology 2001 56 6 730 736 11274306
  3. [3]Aarsland D Andersen K Larsen JP Lolk A Kragh-Sørensen P Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study Arch Neurol 2003 60 3 387 392 12633150
  4. [4]Aarsland D Zaccai J Brayne C A systematic review of prevalence studies of dementia in Parkinson’s disease Mov Disord 2005 20 10 1255 1263 16041803
  5. [5]McKeith I Fairbairn A Perry R Thompson P Perry E Neuroleptic sensitivity in patients with senile dementia of the Lewy body type BMJ 1992 305 6855 673 678 1356550 PMC1882909
  6. [6]Svenningsson P Westman E Ballard C Aarsland D Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment Lancet Neurol 2012 11 8 697 707 22814541
  7. [7]McKeith IG Dickson DW Lowe J et al; for Consortium on DLB Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 2005 65 12 1863 1872 16237129
  8. [10]Religa D Spångberg K Wimo A Edlund AK Winblad B Eriksdotter-Jönhagen M Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry Dement Geriatr Cogn Disord 2012 33 2–3 90 95 22433665
  9. [12]Folstein MF Folstein SE McHugh PR “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 1975 12 3 189 198 1202204
  10. [13]Sharma H Desai N Ganjiwale J Comparison of MMSE to DSM-IV diagnostic criteria for the detection of delirium in medically ill patients with psychiatric referrals Journal of Mental Health and Human Behaviour 2011 16 1 37 42
  11. [14]Richard IH Papka M Rubio A Kurlan R Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002 17 6 1161 1165 12465052
  12. [15]Horimoto Y Matsumoto M Nakazawa H Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson’s disease with dementia J Neurol Sci 2003 216 1 105 108 14607310
  13. [16]Goldmann Gross R Siderowf A Hurtig HI Cognitive impairment in Parkinson’s disease and dementia with lewy bodies: a spectrum of disease Neurosignals 2008 16 1 24 34 18097157
  14. [17]McKeith I Dementia with Lewy bodies and Parkinson’s disease with dementia: where two worlds collide Pract Neurol 2007 7 6 374 382 18024777
  15. [18]McKeith I Mintzer J Aarsland D et al; for International Psychogeriatric Association Expert Meeting on DLB Dementia with Lewy bodies Lancet Neurol 2004 3 1 19 28 14693108
  16. [19]Revuelta GJ Lippa CF Dementia with Lewy bodies and Parkinson’s disease dementia may best be viewed as two distinct entities Int Psychogeriatr 2009 21 2 213 216 19173761
  17. [20]Buter TC van den Hout A Matthews FE Larsen JP Brayne C Aarsland D Dementia and survival in Parkinson disease: a 12-year population study Neurology 2008 70 13 1017 1022 18362281
  18. [22]Vaamonde-Gamo J Flores-Barragán JM Ibáñez R Gudín M Hernández A DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer’s disease Rev Neurol 2005 41 5 276 279 Spanish 16138284
  19. [23]Sorbi S, Hort J, Erkinjuntti T, et al; for EFNS Scientist Panel on Dementia and Cognitive Neurology. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia Eur J Neurol 2012 19 9 1159 1179 22891773
  20. [24]Noe E Marder K Bell KL Jacobs DM Manly JJ Stern Y Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia Mov Disord 2004 19 1 60 67 14743362
  21. [25]Ballard CG Aarsland D McKeith I Fluctuations in attention: PD dementia vs DLB with parkinsonism Neurology 2002 59 11 1714 1720 12473758
  22. [26]Cormack F Aarsland D Ballard C Tovée MJ Pentagon drawing and neuropsychological performance in dementia with Lewy bodies, Alzheimer’s disease, Parkinson’s disease and Parkinson’s disease with dementia Int J Geriatr Psychiatry 2004 19 4 371 377 15065231
  23. [27]Aarsland D Ballard C Larsen JP McKeith I A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia Int J Geriatr Psychiatry 2001 16 5 528 536 11376470
  24. [28]Downes JJ Priestley NM Doran M Ferran J Ghadiali E Cooper P Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson’s disease Behav Neurol 1998 11 3 173 183 22387597
  25. [29]Gnanalingham KK Byrne EJ Thornton A Sambrook MA Bannister P Motor and cognitive function in Lewy body dementia: comparison with Alzheimer’s and Parkinson’s diseases J Neurol Neurosurg Psychiatry 1997 62 3 243 252 9069479 PMC1064153
  26. [30]Johnell C Religa D Eriksdotter M Dementia disorders and drug therapy: a nationwide study of over 7000 patients-data from SveDem Ger Dem Cogn Disord 2013 35 5–6 239 248 23485654
  27. [31]van Laar T De Deyn PP Aarsland D Barone P Galvin JE Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data CNS Neurosci Ther 2011 17 5 428 441 21951368 PMC6493905
  28. [32]Hindle JV The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient J Neural Transm 2013 120 4 649 653 23430276
  29. [33]Weintraub D Somogyi M Meng X Rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis Am J Alzheimers Dis Other Demen 2011 26 6 443 449 22009228 PMC10845532
  30. [34]Rolinski M Fox C Maidment I McShane R Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease Cochrane Database Syst Rev 2012 3 CD006504 22419314 PMC8985413
  31. [36]Merims D Giladi N Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease Parkinsonism Relat Disord 2008 14 4 273 280 17988927
  32. [37]Ballard C Kahn Z Corbett A Treatment of dementia with Lewy bodies and Parkinson’s disease dementia Drugs Aging 2011 28 10 769 777 21970305
  33. [38]Sköldunger A Wimo A Johnell K Net costs of dementia in Sweden – an incidence based 10 year simulation study Int J Geriatr Psychiatry 2012 27 11 1112 1117 22298311

Cited by

Sorted by citations

Metadata

Authors
Fereshtehnejad, S.-M., Religa, D., Westman, Lökk, J., Eriksdotter, M., & Aarsland, D.
Affiliations
  • Karolinska Institutet (SE)
  • Karolinska University Hospital (SE)
  • Stavanger University Hospital (NO)
Corresponding author
Fereshtehnejad, Seyed-Mohammad
ORCID
Venue
Neuropsychiatric Disease and Treatment
Publisher
Informa UK Limited
Published
2013-06
Volume
9
Pages
927
ISSN
1176-6328 (ISSN-L)
DOI
10.2147/ndt.s45840
PMC
PMC3700781
OpenAlex
W2017006381
Cited by
42
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 4 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 5
FWCI
2.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Stiftelsen för Gamla Tjänarinnor
  • Karolinska Institutet
  • Vetenskapsrådet (523‐2012‐2291, 2012-02291)
  • Swedish Brain Power
  • Svenska Läkaresällskapet
  • Alzheimerfonden
  • Sveriges Kommuner och Landsting
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
dementia with Lewy bodies, Parkinson's disease dementia, dementia diagnosis, diagnostic workup, cholinesterase inhibitors, memantine, antipsychotic drugs, antidepressants, cognitive impairment, age of onset, dementia registry, differential diagnosis of dementia, Mini-Mental State Examination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review